Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Cross-Sectional Study

Predictors of Treatment Outcome and Clinical Profile among Guillain- Barre Syndrome Patients in South India

Author(s): Nitin Joseph* and Soumya Shrigiri

Volume 18, Issue 4, 2023

Published on: 27 October, 2023

Page: [258 - 268] Pages: 11

DOI: 10.2174/0115748871254419231019053136

Price: $65

Abstract

Background: Guillain-Barre syndrome (GBS) is one of the principal causes of acute neuromuscular weakness and paralysis worldwide. Its clinic-epidemiological profile and factors influencing its treatment outcomes in developing countries are very minimally studied.

Objective: The study aimed to find out the risk factors, clinical presentation, management, and predictors of treatment outcomes among GBS patients admitted in two tertiary care hospitals.

Materials and Methods: Medical records of 121 inpatients with GBS confirmed based on the Brighton criteria over the recent five-year period from June 2017 to May 2022 were examined. Assessment of the severity of GBS was done using the Hughes functional grading scale.

Results: The mean age at onset was 36.8 ± 18.9 years. The majority of the patients [82 (67.8%)] were males. Antecedent illnesses within 1 month of onset of GBS were present among 34 (28.1%) patients. The majority of them developed respiratory tract illnesses [13 (38.2%)]. Recurrent history of GBS was observed among 4 (3.3%) patients. The median time gap between the onset of antecedent illnesses and the onset of GBS was 5 days (IQR 3, 10). The most common symptom among GBS patients was the weakness of the muscles of the extremities [117 (96.7%)]. The pattern of progression of weakness among 53 (45.3%) of these patients was from the lower to upper limbs. The most common sign noted was hypotonia [64(52.9%)]. Complications due to GBS were observed among 12 (9.9%) patients. The most common complication among them was respiratory distress in 11 (91.7%) patients, followed by autonomic dysfunctions in 8 (66.7%). Albuminocytological dissociation in cerebrospinal fluid was noted among 48 (39.7%) patients. The majority of patients in nerve conduction studies had acute inflammatory demyelinating polyneuropathy [61(50.4%)]. The majority of the GBS patients [68 (56.2%)] were treated using intravenous immunoglobulin (IVIG). 95 (78.5%) patients improved with treatment at the time of discharge. In multivariable analysis, the absence of antecedent illnesses (p =0.029), Brighton’s diagnostic certainty levels 1 and 2 of GBS (p =0.024), and being on IVIG treatment (p =0.05) were associated with improvement in disease condition among the patients.

Conclusion: Appropriate diagnosis of GBS using both clinical and laboratory evidence and providing appropriate treatment along with more supervision among GBS patients with a history of antecedent illnesses will help improve their prognosis at the time of discharge.

[1]
Bragazzi NL, Kolahi AA, Nejadghaderi SA, et al. Global, regional, and national burden of Guillain–Barré syndrome and its underlying causes from 1990 to 2019. J Neuroinflammation 2021; 18(1): 264.
[http://dx.doi.org/10.1186/s12974-021-02319-4] [PMID: 34763713]
[2]
Gupta M, Daid S. Etiology and Outcomes of Acute Flaccid Paralysis in Adults: A Study in Tertiary Care Center. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.05.27.20104620]
[3]
Mohsin N, Asimi R. Clinical profile of acute flaccid paralysis: A study from North India, Kashmir. CHRISMED Journal of Health and Research 2017; 4(1): 27-32.
[http://dx.doi.org/10.4103/2348-3334.196059]
[4]
Saple P, Singh S, Gupta N, Gupta AM, Chandel AS, Waghela S. Clinical profile and predictors for outcome in children presenting with Guillain–Barré syndrome. J Family Med Prim Care 2020; 9(10): 5316-9.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_951_20] [PMID: 33409208]
[5]
National Institute of Neurological Disorders and Stroke. Guillain-Barré syndrome Fact Sheet: Bethesda. 2018. Available from: https://www.ninds.nih.gov/guillain-barre-syndrome-fact-sheet (Accessed on: 7th October 2022).
[6]
Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol 2019; 15(11): 671-83.
[http://dx.doi.org/10.1038/s41582-019-0250-9] [PMID: 31541214]
[7]
Bhagat SK, Sidhant S, Bhatta M, Ghimire A, Shah B. Clinical profile, functional outcome, and mortality of guillain-barre syndrome: A five-year tertiary care experience from Nepal. Neurol Res Int 2019; 2019: 1-5.
[http://dx.doi.org/10.1155/2019/3867946] [PMID: 31275647]
[8]
Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of guillain-barre syndrome and validation of brighton criteria. Brain 2014; 137(1): 33-43.
[http://dx.doi.org/10.1093/brain/awt285] [PMID: 24163275]
[9]
Shi M, Zhu J, Deng H. Clinical characteristics of intravenous injection of monosialotetrahexosyl ganglioside sodium-related guillain-barre syndrome. Front Neurol 2019; 10: 225.
[http://dx.doi.org/10.3389/fneur.2019.00225] [PMID: 30930839]
[10]
Vyas A, Jaiswal K, Swami S, Rankawat M. Clinical profile of adults with Guillain Barre Syndrome in North-West Rajasthan, India. International Journal of Advances in Medicine 2016; 3: 519-22.
[http://dx.doi.org/10.18203/2349-3933.ijam20162203]
[11]
Khairani AF, Karina M, Siswanti LH, Dewi MM. Clinical profile of pediatric guillain-barré syndrome: A study from National Referral Hospital in West Java, Indonesia. Biomed Pharmacol J 2019; 12: 2043-8.
[http://dx.doi.org/10.13005/bpj/1837]
[12]
Sudulagunta SR, Sodalagunta MB, Sepehrar M, et al. Guillain-Barré syndrome: clinical profile and management. Ger Med Sci 2015; 13: Doc16.
[PMID: 26421004]
[13]
Saravanan P. A study on Guillain Barre’s syndrome clinical profile and treatment outcome 2008.
[14]
Habib R, Saifuddin M, Islam R, Rahman A, Bhowmik NB, Haque MA. Clinical profile of guillain barre’ syndrome-observations from a tertiary care Hospital of Bangladesh. BIRDEM Medical Journal 2017; 7(1): 38-42.
[http://dx.doi.org/10.3329/birdem.v7i1.31270]
[15]
Prabhash R, Chouksey D, Garg R. Clinical profile, electrophysiological findings, treatment response of Guillain Barre Syndrome: A retrospective study from tertiary care centre in Central India. EJMCM 2022; 9: 4867-78.
[16]
Rigo DFH, Ross C, Hofstatter LM, Ferreira MFAPL. Guillain Barré syndrome: epidemiological clinical profile and nursing care. Enferm Glob 2020; 57: 376-89.
[17]
Kanjalkar MM, Sasturkar MK, Biradar SB. Clinical profile and treatment outcomes of patients of guillain-barre syndrome in tertiary care centre. IJCMAAS 2020; 25: 38-42.
[18]
Manju KD, Dogra VD, Singh G. Harita. Guillain-Barre; Syndrome: Clinical Profile. Journal of Current Medical Research and Opinion 2019; 2: 378-82.
[19]
John J, Kannan A. Clinical profile of Guillain Barre syndrome in a tertiary care centre. International Journal of Research in Medical Sciences 2014; 2(2): 445-7.
[http://dx.doi.org/10.5455/2320-6012.ijrms20140513]
[20]
Tullu MS, Rangan RS, Deshmukh C, Mondkar S, Agrawal M. Clinical profile and outcome of guillain–barre syndrome in pediatric patients admitted to a tertiary care centre: A retrospective study. Neurol India 2021; 69(1): 81-4.
[http://dx.doi.org/10.4103/0028-3886.310112] [PMID: 33642275]
[21]
Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, Eds. Harrison’s Principles of Internal Medicine. (20th ed.), 2018.
[22]
Dave P, Diwan AG, Singh B, Thavare S, Bonde K, Desai B. Study of clinical profile of Guillain Barre Syndrome. J Med Sci Clin Res 2017; 5(5): 22461-6.
[http://dx.doi.org/10.18535/jmscr/v5i5.192]
[23]
Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 2010; 74(7): 581-7.
[http://dx.doi.org/10.1212/WNL.0b013e3181cff735] [PMID: 20157160]
[24]
Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin 2013; 31(2): 491-510.
[http://dx.doi.org/10.1016/j.ncl.2013.01.005] [PMID: 23642721]
[25]
Bradley WG, Daroff RB, Fenichel GM, Jankovic J. Neurology in Clinical Practice. (5th ed.). 2007; 2.
[26]
Kalita J, Kumar M, Misra UK. Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-Barré syndrome in India. Muscle Nerve 2018; 57(5): 761-5.
[http://dx.doi.org/10.1002/mus.25992] [PMID: 29053890]
[27]
Bourque PR, Brooks J, Warman-Chardon J, Breiner A. Cerebrospinal fluid total protein in Guillain–Barré syndrome variants: correlations with clinical category, severity, and electrophysiology. J Neurol 2020; 267(3): 746-51.
[http://dx.doi.org/10.1007/s00415-019-09634-0] [PMID: 31734909]
[28]
Infusion Associates Management. Infusion therapy treatment for Guillain-Barre Syndrome (GBS) 2022. Available from: https://infusionassociates.com/infusion-therapy/guillain-barre-syndrome/#:~:text=IVIg%20delivers%20donor%20plasma%20to,weeks%20of%20the%20symptoms'%20onset (Accessed on: 7th October 2022).
[29]
Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016; 10(10): CD001446.
[PMID: 27775812]
[30]
Papri N, Doets AY, Mohammad QD, et al. Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh. Ann Clin Transl Neurol 2022; 9(8): 1264-75.
[http://dx.doi.org/10.1002/acn3.51627] [PMID: 35908170]
[31]
Luijten LWG, Doets AY, Arends S, et al. Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2023; 94(4): 300-8.
[http://dx.doi.org/10.1136/jnnp-2022-329937] [PMID: 36428088]
[32]
Koul RL, Alfutaisi A. Prospective study of children with Guillain-Barre syndrome. Indian J Pediatr 2008; 75(8): 787-90.
[http://dx.doi.org/10.1007/s12098-008-0099-1] [PMID: 18581067]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy